ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Feb 03, 2023 11:01 JST
Source:
Ocumension Therapeutics
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
HONG KONG, Feb 03, 2023 - (ACN Newswire) - Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, collectively the "Group", stock code: 1477), a China-based ophthalmic pharmaceutical platform company, announces that the phase I clinical trial of OT-202 (tyrosine kinase inhibitor), a class I new drug developed by the Company for the treatment of dry eye, has been completed successfully.
The phase I clinical trial of OT-202 was designed as a randomized, double-masked, placebo-controlled clinical trial on the safety, tolerance and pharmacokinetic properties of its single/multiple administration on healthy adult subjects in China.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "OT-202 (tyrosine kinase inhibitor) is a class I innovative drug developed by the Company for the treatment of moderate to severe dry eye. A total of 30 subjects were enrolled for the phase I clinical trial in China. OT-202 demonstrated good safety and tolerability profile in healthy adult subjects in the phase I clinical trial. Currently, we are in the process of advancing the study for the phase II clinical trial."
The mechanism of action of OT-202 is that the dual-targeted inhibitor of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor achieves a synergistic effect in the treatment of dry eye diseases and inhibits the inflammatory response.
More information about Ocumension Therapeutics:
https://www.ocumension.com/
Source: Ocumension Therapeutics
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
NEC and the Cote d'Ivoire Ministry of Agriculture enhance agricultural efficiency through digital technology
Oct 22, 2025 20:55 JST
Fujitsu and Kawasaki Frontale sign global Sports for Nature Framework in Japan first
Oct 22, 2025 18:16 JST
Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing
Oct 21, 2025 23:00 JST
MHI Thermal Systems to Launch New 2026 Models of the S Series High-Capacity Residential-Use Air-Conditioners for the Japanese Market
Oct 21, 2025 22:10 JST
New Land Cruiser "FJ" Makes World Premiere
Oct 21, 2025 21:29 JST
Sharp Initiates Collaboration with ARAV Corporation for Remote Control Solutions of Construction Machinery Utilizing Satellite Communication
Oct 21, 2025 21:00 JST
Hitachi and OpenAI form strategic partnership centered on global AI data center expansion
Oct 21, 2025 20:06 JST
Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership
Oct 21, 2025 16:45 JST
Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)"
Oct 21, 2025 11:00 JST
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST
Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST
Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST
Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST
More Latest Release >>
Related Release
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema
December 20 2023 20:51 JST
Ocumension Therapeutics Announces 2023 Interim Results
August 24 2023 23:35 JST
Ocumension Therapeutics Announces 2022 Annual Results
March 30 2023 22:29 JST
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
March 13 2023 18:30 JST
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
February 14 2023 10:57 JST
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China
February 01 2023 10:00 JST
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively
January 30 2023 11:38 JST
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
March 20 2021 10:10 JST
More Press release >>